Elanco Animal Health Incorporated (NYSE:ELAN) Shares Purchased by Geode Capital Management LLC

Geode Capital Management LLC increased its holdings in shares of Elanco Animal Health Incorporated (NYSE:ELAN) by 3.9% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,420,883 shares of the company’s stock after purchasing an additional 204,257 shares during the quarter. Geode Capital Management LLC’s holdings in Elanco Animal Health were worth $187,773,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in ELAN. Tompkins Financial Corp purchased a new position in Elanco Animal Health during the 1st quarter valued at about $27,000. Captrust Financial Advisors purchased a new position in Elanco Animal Health during the 1st quarter valued at about $28,000. Berman Capital Advisors LLC boosted its holdings in Elanco Animal Health by 155.2% during the 2nd quarter. Berman Capital Advisors LLC now owns 929 shares of the company’s stock valued at $32,000 after acquiring an additional 565 shares during the period. Quadrant Capital Group LLC boosted its holdings in Elanco Animal Health by 216.6% during the 1st quarter. Quadrant Capital Group LLC now owns 1,200 shares of the company’s stock valued at $35,000 after acquiring an additional 821 shares during the period. Finally, Proequities Inc. boosted its holdings in Elanco Animal Health by 37.8% during the 1st quarter. Proequities Inc. now owns 1,239 shares of the company’s stock valued at $36,000 after acquiring an additional 340 shares during the period. Institutional investors own 99.58% of the company’s stock.

Shares of NYSE ELAN opened at $32.03 on Thursday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 1.00 and a current ratio of 1.72. Elanco Animal Health Incorporated has a fifty-two week low of $26.72 and a fifty-two week high of $37.49. The firm has a market capitalization of $15.15 billion, a PE ratio of 35.76, a price-to-earnings-growth ratio of 0.65 and a beta of 0.83. The stock’s 50-day simple moving average is $32.49 and its 200-day simple moving average is $33.14.

Elanco Animal Health (NYSE:ELAN) last issued its earnings results on Sunday, August 8th. The company reported $0.28 earnings per share for the quarter, topping the consensus estimate of $0.26 by $0.02. Elanco Animal Health had a positive return on equity of 5.24% and a negative net margin of 16.02%. The business had revenue of $1.28 billion for the quarter, compared to analyst estimates of $1.24 billion. During the same quarter last year, the company earned ($0.09) EPS. The business’s quarterly revenue was up 118.3% on a year-over-year basis. On average, sell-side analysts forecast that Elanco Animal Health Incorporated will post 1 earnings per share for the current fiscal year.

ELAN has been the subject of a number of research analyst reports. Credit Suisse Group initiated coverage on Elanco Animal Health in a report on Thursday, August 5th. They set an “outperform” rating and a $38.00 target price for the company. Zacks Investment Research cut Elanco Animal Health from a “hold” rating to a “sell” rating in a research note on Monday. One analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, Elanco Animal Health has an average rating of “Buy” and a consensus target price of $37.75.

In other Elanco Animal Health news, Director Michael J. Harrington purchased 3,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 11th. The shares were purchased at an average cost of $28.98 per share, for a total transaction of $86,940.00. Following the completion of the purchase, the director now directly owns 25,684 shares in the company, valued at $744,322.32. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Jeffrey N. Simmons purchased 16,850 shares of the firm’s stock in a transaction that occurred on Wednesday, August 11th. The stock was acquired at an average price of $29.70 per share, for a total transaction of $500,445.00. Following the completion of the purchase, the chief executive officer now owns 568,577 shares of the company’s stock, valued at $16,886,736.90. The disclosure for this purchase can be found here. Insiders have bought a total of 45,528,788 shares of company stock worth $421,545,062 in the last three months. Corporate insiders own 6.11% of the company’s stock.

About Elanco Animal Health

Elanco Animal Health, Inc engages in the innovation, development, manufacture and market products for companion and food animals. It offers products through the following four categories: Companion Animal Disease Prevention, Companion Animal Therapeutics, Food Animal Future Protein & Health, and Food Animal Ruminants & Swine.

See Also: Intrinsic Value

Want to see what other hedge funds are holding ELAN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Elanco Animal Health Incorporated (NYSE:ELAN).

Institutional Ownership by Quarter for Elanco Animal Health (NYSE:ELAN)

Receive News & Ratings for Elanco Animal Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Elanco Animal Health and related companies with MarketBeat.com's FREE daily email newsletter.